Perhaps no field better exemplifies the diagnostic promise of advanced technologies — and the possibilities for hype and disappointment — than advanced genetic screening and the accompanying aspiration of personalized genomic medicine.

This issue's Point-Counterpoint concerns the promising but complex technology of whole genome sequencing (WGS). The prospect of a thousand-dollar WGS brings such advanced technologies potentially into the realm of everyday clinical care.

Our Point essay by Perry Payne of George Washington University argues that WGS should be reimbursed, without patient cost sharing, under provisions of the Patient Protection and Affordable Care Act (ACA). Noting the potential medical and public health benefits associated with WGS, Payne suggests that the ACA can be used “as a tool to prevent disparities in access to genome information in the United States and avoid the development of a two-tiered health system based on those with and without genome sequence data.”

Wisconsin bioethicists Pilar...

You do not currently have access to this content.